Literature DB >> 25312053

Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.

Francesco Bertagna1, Laura Evangelista2, Arnoldo Piccardo3, Mattia Bertoli4, Giovanni Bosio4, Raffaele Giubbini4, Emanuela Orlando5, Giorgio Treglia6.   

Abstract

AIM: Our study has aimed to establish the prevalence and pathological nature of fluorine-18-fluorodeoxyglucose ((18)F-FDG) breast incidental uptake (BIU) in patients studied for non-malignant breast tumours and then to compare our data obtained in three Italian nuclear medicine centres with those available in literature.
MATERIAL AND METHODS: We retrospectively evaluated 42,927 (18)F-FDG-PET/CT scans performed on patients studied in three Italian Nuclear Medicine Centres. All patients underwent (18)F-FDG-PET/CT for oncologic purposes not related to breast disease.
RESULTS: Among 42,927 scans, a BIU was identified in 79 (0.18%) patients, 75 (95%) female and 4 (5%) male with an average age of 62 ± 17 years. Twenty-five out of 35 (71.5%) BIUs were malignant and 10/35 (28.5%) benign. Among the 25/35 incidentalomas that were malignant, 12/25 (48%) were infiltrating ductal carcinoma, 5/25 (20%) ductal carcinoma (infiltrating and in situ), 4/25 (16%) lobular carcinoma, 2/25 (8%) ductal carcinoma in situ and 2/25 (8%) were metastases from the primary tumour under investigation. Of the 10 BIUs that were benign in the histological examination, after further investigations it was found that 9/10 (90%) were fibroadenomas and 1/10 (10%) was a benign lesion not better specified. The lesion to liver or to blood-pool SUVmax ratio in malignant lesions is significantly higher than in benign ones.
CONCLUSIONS: Our multicenter study demonstrates that, although they are uncommon, BIUs show a high percentage of malignancy and therefore requires further research.
Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG; Breast; Incidentaloma; Mama; PET/CT; PET/TAC

Mesh:

Substances:

Year:  2014        PMID: 25312053     DOI: 10.1016/j.remn.2014.08.003

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  5 in total

1.  Multicentre study of 18F-FDG-PET/CT prostate incidental uptake.

Authors:  Francesco Bertagna; Arnoldo Piccardo; Bassam Dib; Mattia Bertoli; Federica Fracassi; Giovanni Bosio; Raffaele Giubbini; Giorgio Biasiotto; Luca Giovanella; Giorgio Treglia
Journal:  Jpn J Radiol       Date:  2015-07-08       Impact factor: 2.374

2.  Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.

Authors:  F J Pena Pardo; A M García Vicente; M Amo-Salas; J F López-Fidalgo; J A Garrido Robles; J Á de Ayala Fernández; P Del Saz Saucedo; M Muñoz Pasadas; A Soriano Castrejón
Journal:  Clin Transl Oncol       Date:  2016-05-02       Impact factor: 3.405

3.  Clinical-Diagnostic Relevance of Breast "Incidentaloma" Detected During 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography: Correlation with Radiological Imaging and Histopathology.

Authors:  Stefano Panareo; Luca Urso; Alberto Nieri; Matteo Caracciolo; Giorgia Valpiani; Pietro Torricelli; Antonio Frassoldati; Corrado Cittanti; Marco Rollo; Mirco Bartolomei
Journal:  Indian J Nucl Med       Date:  2021-12-15

Review 4.  Prevalence of focal incidental breast uptake on FDG-PET/CT and risk of malignancy: a systematic review and meta-analysis.

Authors:  Else Marie Aarstad; Petter Nordhaug; Mohammad Naghavi-Behzad; Lisbet Brønsro Larsen; Oke Gerke; Malene Grubbe Hildebrandt
Journal:  Eur J Hybrid Imaging       Date:  2019-09-30

5.  Prevalence of additional primary malignancies detected incidentally on PET/CT.

Authors:  Joseph C Lee; Marcelo Santos Teles
Journal:  Radiol Bras       Date:  2019 Sep-Oct
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.